3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
3
Phase 4
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
56
Lymphoma, Large B-Cell, Diffuse
55
Lymphoma, Follicular
48
Lymphoma
47
Leukemia, Lymphocytic, Chronic, B-Cell
45
Lymphoma, Mantle-Cell
41
Lymphoma, B-Cell, Marginal Zone
24
Lymphoma, B-Cell
22
Waldenstrom Macroglobulinemia
17
Hodgkin Disease
16
Burkitt Lymphoma
16
Leukemia
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Recurrence
10
Lymphoma, Large-Cell, Immunoblastic
9
Neoplasms
7
Multiple Myeloma
6
Myelodysplastic Syndromes
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, T-Cell, Cutaneous
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, Extranodal NK-T-Cell
4
Leukemia, Hairy Cell
4
Intraocular Lymphoma
4
Hematologic Neoplasms
4
Sezary Syndrome
3
Mycosis Fungoides
3
Lymphoma, T-Cell
3
Lymphoma, Primary Effusion
3
Immunoblastic Lymphadenopathy
3
Interventions
Cyclophosphamide
5
fludarabine
3
fludarabine phosphate
2
Mesna
2
Antigens, CD19
2
navitoclax
1
ibrutinib
1
bempegaldesleukin
1
acalabrutinib
1
Vincristine
1
Stem Cell Transplantation
1
Rituximab
1
Prednisone
1
Nivolumab
1
Mycophenolic Acid
1
Melphalan
1
Lenalidomide
1
KW-2478
1
Interleukin-2
1
Hsp90 inhibitor KU757
1
Filgrastim
1
Doxorubicin
1
CTL019 chimeric antigen receptor
1
Bortezomib
1
Bone Marrow Transplantation
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia, B-Cell
×
Rituximab
×
Clear all
NCT06564038
2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2
Recruiting
408 enrolled